SARS-Cov-2 has turned out to be a pernicious pathogen as it spread through global community at large, especially in terms of the unexpected diversity of symptoms and complications in those infected.  Worst of all, this virus has an extended asymptomatic presentation during which time an infected host unknowingly infects others.

Many candidate vaccines are in development and several are in later-phase trials.  Each candidate may be distinct in the particulars of its design, but candidates can be grouped into general categories, e.g., RNA-based, DNA-based, Recombinant protein-based, Viral vector-based vaccines, Live attenuated,  and Inactivated vaccines (see SARS-CoV-2 Vaccines: Status Report, Immunity, 2020 Apr 14; 52(4): 583–589).

The pressure of the times drives the development final formulation (adjuvant, etc), trial design and execution, manufacture, and distribution of a vaccine for general release, however, we know the need for full and thorough testing to determine the dosing regimen and, above all, the safety profile in a broad population.

The Precision Covid-19 Vaccines Virtual Summit is focused on the practical issues of testing these different vaccine types and the issues that need to be addressed to bring such novel vaccines to market.  In addition, we welcome speakers who can discuss the risks of “opening too soon” vs maintaining isolation (domestic violence, suicides) as well as on educating the public to stem anti-vaxxer sentiments.

If you are a clinician, research scientist, or regulator, this conference is one you won’t want to miss. Please join us for the world’s most informative conference for precision medicine with leaders from academia, biotech, pharmaceuticals, diagnostics, clinical research, healthcare and regulatory bodies.

We invite you to join us in for the Precision COVID-19 Vaccines Virtual Summit on October 5, 2020 with a line-up of speakers who will address these points and more:

  • Overview of natural history in host, in a population – how the virus moved from globally
  • Genomic studies of virus
  • Who will respond to vaccine, who may not?
  • Overview of immune response to SARS-Cov-2 insult – diversity of symptoms and natural history
  • Development and types of Vaccines
  • Compliance – address the anti-vaxxers
  • Safety and efficacy
  • Scale-up and distribution – scaling up the manufacturing process for different COVID vaccine approaches
  • Role of marketing and business modeling
  • Trial design and recruitment – inclusion/exclusion criteria
  • Data collection and data review for inclusion in analysis
  • Assaying for response – what markers are the most critical?
  • Alternative treatments – anti-viral drugs, innate immunity, plasma treatment
  • Can plasma from vaccinated subjects be used to treat those infected but cannot tolerate a vaccination?
  • Lessons learned to facilitate precision vaccine approaches in the future.
  • Augmented Intelligence – empowering the physician as partner with AI
  • Telemedicine – can diagnostics be done over the phone? or is this the path to triage?
  • Partnerships among diagnostics companies (design, develop, manufacture), vaccines (design, develop, manufacture)
  • Role of CMS – coverage, reimbursement

Who should attend:

  • Executives and Decision Makers – CEOs, CTOs, CMOs, and CSOs
  • Research, Development, and Practicing Clinicians
  • Genomic, Proteomic Analysts
  • Analytical Scientists
  • Regulatory Leaders in Government and Business Affairs groups
  • Economic Planners and Forecasters
  • Marketing Leaders
  • Systems Developers for Systems and Software
  • Artificial and Augmented Intelligence Developers